38 Results for "

SLE

" in MedChemExpress (MCE) Product Catalog:
Products (38)

38 Results for "SLE" in MCE Product Catalog:

40
40 Publications Verification
Cat. No.: HY-108882B
CAS No.: 9003-98-9
Target:  

DNA/RNA Synthesis

Research Areas:  

Inflammation/Immunology

DNase I is an enzyme that degrades DNA. DNase I is mainly produced by digestive system organs, such as the pancreas and parotid gland. Three types of DNase I are known in mammals: pancreatic type, parotid type, and pancreatico-parotid type. DNase I plays a key role in the cleavage of extracellular DNA, and is critical for limiting inflammatory responses and maintaining homeostasis. DNase I is responsible for digesting extracellular nucleoproteins, which may be essential for preventing autoimmune responses. Decreased DNase I activity may be associated with the onset and progression of systemic lupus erythematosus (SLE). DNase I (RNase & Protease free) is a molecular biology-grade DNase I purified by chromatography to remove RNase and protease .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P9952
CAS No.: 356547-88-1
Synonyms: LymphoStat B

Target:  

TNF Receptor CD20

Research Areas:  

Inflammation/Immunology Cancer

Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P99168
CAS No.: 1326232-46-5
Synonyms: MDX-1333; MEDI-546

Target:  

IFNAR

Research Areas:  

Inflammation/Immunology

Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-76082
CAS No.: 98-79-3
L-Pyroglutamic acid is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid is the biologically active enantiomer in humans. Pyroglutamic acid is an intermediate in glutathione metabolism. L-Pyroglutamic acid can be used as a biomarker for systemic lupus erythematosus (SLE) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-76082A
CAS No.: 28874-51-3
L-Pyroglutamic acid sodium is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid sodium is the biologically active enantiomer in humans. Pyroglutamic acid is an intermediate in glutathione metabolism. L-Pyroglutamic acid sodium can be used as a biomarker for systemic lupus erythematosus (SLE) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-150095
CAS No.: 3065657-02-2
Purity:  96.47%
Target:  

IFNAR

Research Areas:  

Inflammation/Immunology

YE6144 free base is a selective prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 free base suppresses the disease course and is especially effective in remission maintenance in a mouse model of systemic lupus erythematosus (SLE). YE6144 free base can be used for SLE research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108882C
CAS No.: 9003-98-9
Target:  

DNA/RNA Synthesis

Research Areas:  

Inflammation/Immunology

DNase I is an enzyme that degrades DNA. DNase I is mainly produced by digestive system organs, such as the pancreas and parotid gland. Three types of DNase I are known in mammals: pancreatic type, parotid type, and pancreatico-parotid type. DNase I plays a key role in the cleavage of extracellular DNA, and is critical for limiting inflammatory responses and maintaining homeostasis. DNase I is responsible for digesting extracellular nucleoproteins, which may be essential for preventing autoimmune reactions. Decreased DNase I activity may be associated with the occurrence and development of systemic lupus erythematosus (SLE). DNase I (filtered) is filtered through a 0.22 μM membrane and is not tested for pyrogenicity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99414
CAS No.: 1523164-68-2
Synonyms: AMG 557
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
loading...
    loading...
Cat. No.: HY-P99219
CAS No.: 1006877-41-3
Synonyms: MEDI-545; MDX 1103

Target:  

IFNAR

Research Areas:  

Inflammation/Immunology

Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
loading...
    loading...
Cat. No.: HY-P99325
CAS No.: 252662-47-8
Synonyms: IDEC-131; Anti-Human CD40 ligand Recombinant Antibody

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
loading...
    loading...
Cat. No.: HY-147390
CAS No.: 1208448-95-6
Purity:  99.88%
MIF098 is a macrophage migration inhibitory factor (MIF) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research .
loading...
    loading...
Cat. No.: HY-153701S
CAS No.: 2417135-66-9
Synonyms: Envudeucitinib; ESK-001
Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .
loading...
    loading...
Cat. No.: HY-P99529
CAS No.: 1804910-11-9
Synonyms: BAX1810; TAK-752; SM101

Target:  

Fc Receptor (FcR)

Research Areas:  

Inflammation/Immunology

Valziflocept (BAX1810) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE) .
loading...
    loading...
Cat. No.: HY-P6084
CAS No.: 1541177-35-8
RP-220 is a renalase peptide targeting NLRP3. RP220 has anti-inflammatory and anti-apoptotic activities. RP220 inhibits renal tubular epithelial cells apoptosis with alkaline insult by activating MAPK signaling pathway. RP220 significantly inhibits NLRP3 expression and reduces macrophage infiltration and kidney tissue damage in acute kidney injury (AKI) mice model. RP-220 can be uses for systemic lupus erythematosus (SLE) and its complication lupus nephritis (LN) research .
loading...
    loading...
Cat. No.: HY-P3560
CAS No.: 433922-67-9
Synonyms: TV 4710
Target:  

Apoptosis

Research Areas:  

Inflammation/Immunology

Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .
loading...
    loading...
Cat. No.: HY-76082R
CAS No.: 98-79-3
L-Pyroglutamic acid (Standard) is the analytical standard of L-Pyroglutamic acid (HY-76082). This product is intended for research and analytical applications. L-Pyroglutamic acid is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid is the biologically active enantiomer in humans. Pyroglutamic acid is an intermediate in glutathione metabolism. L-Pyroglutamic acid standard can be used as a biomarker for systemic lupus erythematosus (SLE) .
loading...
    loading...
Cat. No.: HY-156466
CAS No.: 2848664-42-4
Purity:  99.95%
Research Areas:  

Inflammation/Immunology

QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM,TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .
loading...
    loading...
Cat. No.: HY-105037A
Purity:  98.89%
Synonyms: IPP-201101 TFA
Target:  

Autophagy

Research Areas:  

Inflammation/Immunology

Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .
loading...
    loading...
Cat. No.: HY-176553
CAS No.: 3023713-87-0
KBD4466 is an orally active potent TLR7 and TLR8 inhibitor with IC50s of 0.9 nM and 2.8 nM, respectively. KBD4466 inhibits the expression of inflammatory cytokines IL-6 and IFN-α. KBD4466 improves disease progression and survival in the BXSB/MpJ mouse model of Systemic Lupus Erythematosus (SLE). KBD4466 can be used in the study of autoimmune diseases .
loading...
    loading...
Cat. No.: HY-148631
CAS No.: 2728727-91-9
Target:  

BCL6

Research Areas:  

Inflammation/Immunology Cancer

GSK137 is an orally active, potent and selective B-cell lymphoma 6 (BCL6) inhibitor. GSK137 blocks the interaction between BCL6 and corepressors (e.g., SMRT), reducing the number of germinal center B cells. GSK137 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and B-cell-related tumors such as diffuse large B-cell lymphoma .
loading...
    loading...